Studies, Trials, and Important Resources

Below is a list of clinical studies on cannabinoids and Cannabidiol (CBD). There is a growing amount of material being published as the CBD industry continues to grow. Make sure to check this page often to ensure you have access to the latest research and discoveries.


Cannabidiol in Anxiety and Sleep: A Large Case Series

Objective: To determine whether CBD helps improve sleep and/or anxiety in a clinical population.

Conclusion: Cannabidiol may hold benefits for anxiety-related disorders. Controlled clinical studies are needed.



Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

Background: The Dravet syndrome is a complex childhood epilepsy disorder that is associated with drug-resistant seizures and a high mortality rate. We studied cannabidiol for the treatment of drug-resistant seizures in the Dravet syndrome.

Result: Among patients with the Dravet syndrome, cannabidiol resulted in a greater reduction in convulsive-seizure frequency than placebo and was associated with lower rates of adverse events.



Clinical Trials of Cannabidiol for Epilepsy

Preliminary Results: Multicenter data from the Dravet syndrome study found that seizures were reduced by 39 percent in children treated with CBD versus only 16 percent in the placebo group. “That’s a modest difference, but statistically significant,” Dr. Wirrell says. “CBD is not a cure, but it could potentially be beneficial for children with Dravet syndrome.”



Therapeutical Use of the Cannabinoids in Psychiatry

Objective: To review the main advances related to the potential therapeutic use of cannabinoid compounds in psychiatry.

Conclusion: Cannabinoids may be of great therapeutic interest to psychiatry; however, further controlled trials are necessary to confirm the existing findings and to establish the safety of such compounds.


Cannabidiol Reverses Attentional Bias to Cigarette Cues in a Human Experimental Model of Tobacco Withdrawal

Background: Cannabidiol (CBD), a non-intoxicating cannabinoid, may be a promising novel smoking cessation treatment due to its anxiolytic properties, minimal side-effects and research showing it may modify drug cue salience. We used an experimental medicine approach with dependent cigarette smokers to investigate if (1) overnight nicotine abstinence, compared with satiety, will produce greater attentional bias (AB), higher pleasantness ratings of cigarette-related stimuli and increased craving and withdrawal; (2) CBD in comparison to placebo, would attenuate AB, pleasantness of cigarette-related stimuli, craving and withdrawal and not produce any side-effects.

Findings: A single 800mg oral dose of cannabidiol (CBD) reduced the salience and pleasantness of cigarette cues, compared with placebo, after overnight cigarette abstinence in dependent smokers. CBD did not influence tobacco craving or withdrawal or any subjectively rated side-effects.


Cannabinoid Science and Educational Resources

Educational Websites

American Academy Cannabinoid Science:

Journal of Cannabis Therapeutics 2004:

Project CBD:

Literature and Evidence Based Publications

Non Psychotropic Plant Cannabinoids Pharmacology:

Tale of Two Cannabinoids—Therapeutic Rationale to CombineTHC and CBD:

Medicine Maker—Excellent Review of Pharma and How it Will Enter the Cannabis Space:

Pain and Cannabis from a Physician:

Cannabis and Anxiety:

Sativex Neuropathy Trial:

Psycedelics and Cannabis Science Therapeutics:

Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex ®, a CannabisBased


Adhd and the Endocannabinoid System:

Clinical Endocannabinoid Deficiency—Can This Concept Explain Benefits in IBS, Fibromylagia,

Migraines and Other Treatment Resistant Conditions?: /25_12/NEL251204R02_Russo_.pdf

Dronabinol for the Treatment of Agitation and Aggressive Behavior in Acutely Hospitalized Severely Demented Patients With Noncognitive Behavioral Symptoms:

Share This